Bioretec Ltd Announces Rights Issue for Shareholders
Bioretec Ltd recently made a significant announcement regarding a new rights issue designed for its existing shareholders. This strategic move, aimed at enhancing shareholder engagement and capital provision, showcases the company's commitment to growth and innovation.
Details of the Rights Issue
The rights issue will permit Bioretec to offer up to 6,156,618 new shares at a subscription price of EUR 1.50 per share. This offering allows current shareholders to exercise their pre-emptive rights, ensuring they can maintain their proportionate ownership in the company.
Exemption Document Prepared
As part of the offering, Bioretec has prepared an exemption document in compliance with the relevant European regulations, ensuring transparency and clarity for all participants. The document outlines the terms and conditions of the offering, providing essential information to shareholders.
Availability of the Exemption Document
The exemption document will be accessible on Bioretec's official website around early June. This allows shareholders to review critical information about the offering, including potential effects on their investment and the company’s plans moving forward.
Investor Presentation Scheduled
In conjunction with the rights issue, Bioretec plans to host a recorded investor presentation to discuss the initiative and answer common investor questions. This presentation will provide further insights into the company's growth strategy and the expected benefits of this rights issue.
Subscription Period Details
The subscription period for the new shares will commence shortly after the announcement and will remain open for a specified duration, providing ample time for shareholders to participate in this offering.
Trading of Subscription Rights
Additionally, the subscription rights associated with this offering will be transferable and tradable on eligible marketplaces. This feature provides an added layer of flexibility and opportunity for shareholders.
Company Overview
Bioretec is a pioneer in developing biodegradable orthopedic implants. The company’s innovative products focus on promoting natural bone healing, which is a revolutionary approach in orthopedic treatment. Bioretec's commitment to enhancing patient outcomes is at the forefront of their mission.
With a product line that includes the RemeOs™ series, Bioretec addresses a significant need in the orthopedic field, aiming to reduce the necessity for implant removal surgeries and improve overall recoveries for patients globally.
Bioretec’s presence in approximately 40 countries demonstrates its robustness in the medical device market. The company is strategically positioned to expand further into the global orthopedic trauma and spine market, estimated to be worth over USD 10 billion.
Contact Information
For further inquiries regarding the rights issue or company details, investors can reach out to:
Sarah van Hellenberg Hubar-Fisher, Interim CEO, +31 6 1544 8736
Johanna Salko, CFO, +358 40 754 8172
Frequently Asked Questions
What is the purpose of the rights issue?
The rights issue aims to provide existing shareholders with an opportunity to purchase new shares and strengthen the company's capital base.
When will the subscription period begin?
The subscription period is set to commence shortly after the announcement, allowing sufficient time for shareholders to respond.
How many new shares are being offered?
Bioretec will be offering up to 6,156,618 new shares to current shareholders during the rights issue.
Where can I find the exemption document?
Shareholders can access the exemption document on Bioretec's official website around early June.
What are the benefits of participating in the rights issue?
By participating in the rights issue, shareholders can maintain their ownership percentage and potentially benefit from future company growth.
